Table 5. Mean values (M ± SD) of neutrophils, lymphocytes, monocytes, eosinophils and band cells in piperazine treated group (n = 20) and D_oraTG (n = 20).

Groups	Follow up period	Neutrophils (%) (68.06 ± 2.3)1	Lymphocytes (%) (29.17 ± 1.5)1	Monocytes (%) (1.39 ± 0.2)1	Eosinophils (%) (0.0 ± 0.1)1	Band cells (%) (1.39 ± 0.1)1
PipTG	Day 0a	55.00 ± 8.72	41.00 ± 9.80	2.29 ± 1.60	1.57 ± 1.13	0.14 ± 0.38
	Day 7	38.57 ± 7.11b	49.71 ± 8.75b	4.86 ± 3.08	6.71 ± 1.98*	0.14 ± 0.38
	Day 14	34.86 ± 5.55b	56.57 ± 6.68b	3.57 ± 2.23	4.71 ± 3.86	0.29 ± 0.49
	Day 21	40.29 ± 8.85b	51.86 ± 6.23b	2.29 ± 1.60	2.71 ± 2.14	0.14 ± 0.38
	Day 28	43.00 ± 3.16b	52.43 ± 8.26	2.43 ± 2.70	5.00 ± 2.58b	0.14 ± 0.38
DoraTG	Day 0a	56.43 ± 5.33	39.00 ± 6.83	2.29 ± 1.60	1.71 ± 1.50	0.29 ± 0.76
	Day 7	36.57 ± 5.59c	50.86 ± 5.93c	4.57 ± 2.88	7.86 ± 2.11c	0.29 ± 0.49
	Day 14	38.29 ± 5.79c	52.71 ± 4.46c	3.14 ± 1.86	5.43 ± 2.64c	0.43 ± 0.53
	Day 21	41.43 ± 4.35c	51.86 ± 8.40c	2.57 ± 2.23	3.57 ± 2.23	0.43 ± 0.53
	Day 28	38.86 ± 4.56	53.43 ± 5.91c	3.00 ± 2.38	5.57 ± 2.37c	0.43 ± 0.53

Reference values according to Garba et al. (2015).

P_ipTG = piperazine treated group; D_oraTG = doramectin treated group.

^aTreatment day.

^bSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value day 0 in P_ipTG (p < 0.05);

^cSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value at day 0 in D_oraTG (p < 0.05).